Nuvation Bio (NUVB) Receivables - Other (2020 - 2026)

Nuvation Bio (NUVB) has reported Receivables - Other for 7 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other fell 35.46% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 35.46% YoY), while the FY2025 annual figure was $3.3 million, down 7.98% from the prior year.
• Receivables - Other retreated to $3.3 million in Q1 2026 per NUVB's latest filing, from $3.3 million in the prior quarter.
• Across five years, Receivables - Other topped out at $5.5 million in Q3 2025 and bottomed at $2.3 million in Q1 2023.
• Historically, Receivables - Other has averaged $3.5 million across 5 years, with a median of $3.3 million in 2025.
• Annual changes were most pronounced in 2022 — Receivables - Other surged 145.62% — and 2026, when it sank 35.46%.
• Nuvation Bio's Receivables - Other stood at $2.5 million in 2022, then jumped by 48.97% to $3.7 million in 2023, then slipped by 3.57% to $3.6 million in 2024, then retreated by 7.98% to $3.3 million in 2025, then decreased by 0.73% to $3.3 million in 2026.
• Business Quant data shows NUVB's Receivables - Other at $3.3 million in Q1 2026, $3.3 million in Q4 2025, and $5.5 million in Q3 2025.